Andean Pacific HIV Clinical forum – presentation

  Session 1
 
Resistance Characteristics of Integrase Inhibitors
Dr. Charles Boucher, MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands
 Transmitted and Acquired HIV Drug Resistance in Latin America
Dr. Luis Enrique Soto Ramirez, MD
Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Mexico City, Mexico
  Session 2
 
The use of Integrase Inhibitors in Latin America: From guidelines to the Real World
Dr. Ernesto Martinez Buitrago, MD
Universidad del Valle, Cali, Colombia
 
PEP after sexual exposures
Dr. Mauro Schechter, MD, PhD
Federal University of Rio de Janeiro, Rio de Janeiro, Brasil
 Abstract presentations
 Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Infected Chilean Patients. Frequency and Evolution between 2013 and 2016.
Dr. Francisco Sidgman, Chile
Universidad De Chile, Santiago, Chile
 Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) compared with Ritonavir boosted Atazanavir (ATV/r) plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study): Subgroup analyses
Dr. Pedro Cahn, Argentina
Fundación Huésped, Buenos Aires, Argentina
  Clinical case presentation
 
Clinical Case
Dr. Carlos Beltrán, MD
Chilean AIDS Cohort (ChiAC), Santiago, Chile
  Session 3
 
Optimizing use of HIV Diagnostic Technologies in Latin America
Dr. Ricardo Diaz, MD, PhD
NIFESP Laboratorio de Retrovirologia, São Paulo, Brasil
 Abstract presentations
 HIV Proviral DNA is an adequate genetic compartment for detection of resistance mutations associated to integrase inhibitors (INIs) therapy in patient with undetected or low viral load.
Dr. Pablo Ferrer, Chile
SidaChile, Santiago, Chile
  Session 4
 
Reduced Drug Regimens
Dr. Pedro Cahn, MD, PhD
Fundación Huésped, Buenos Aires, Argentina